Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

This was an open-label, randomized study to compare the following regimens with respect to toxicity and antitumor activity: * the maximum tolerated dose (MTD) of ABI-007 300 mg/m\^2 every 3 weeks; * ABI-007 100 mg/m\^2 administered weekly for 3 weeks with a 1 week rest; * ABI-007 150 mg/m\^2 administered weekly for 3 weeks with a 1 week rest; * the standard dose and schedule of Taxotere (100 mg/m\^2 every 3 weeks).